2022年8月16日
;99(7补充1)
结论和下一步
开放获取
帕金森疾病预防
结论和展望
丹妮拉伯格,恩典f . Crotty,杰西·l·Keavney,迈克尔·a·史瓦西,坦尼娅Simuni,卡罗琳·坦纳
第一次出版2022年8月15日,
DOI: https://doi.org/10.1212/WNL.0000000000200793
丹妮拉伯格
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
恩典f . Crotty
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
杰西·l·Keavney
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
迈克尔·a·史瓦西
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
坦尼娅Simuni
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
卡罗琳·坦纳
从神经学部门(D.B. cooper), Ch首页ristian-Albrechts-University,基尔,德国;分子神经生物学实验室(G.F.C.,M.A.S.), Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown; Harvard Medical School (G.F.C., M.A.S.), Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Northwestern University Feinberg School of Medicine (T.S.), Weill Institute for Neuroscience (C.T.), Department of Neurology, University of California - San Francisco; and Parkinson's Disease Research Education and Clinical Center (C.T.), San Francisco Veterans Affairs Medical Center.
文摘
巨大的进步在我们理解病理生理学和临床表现的帕金森病(PD)的前驱阶段提供了一个独特的机会尽早开始治疗干预措施减缓甚至停止发展为临床表现运动PD。帕金森症预防会议”,规划预防帕金森:试验设计研讨会,研讨会”召开会议讨论所有问题之前需要解决的第一个PD预防研究。在这次审查中,我们总结的主要机遇和挑战在PD设计预防试验中,由以下关键试验设计问题:(应该是注册)吗?(测试)吗?(预防措施)吗?和关键问题,当在有前驱症状的疾病(我们应该开始这些试验)吗?我们简略说明这些问题的影响,其意义为一个负责任的,可持续的和富有成果的进一步规划预防试验。尽管已经取得了很大的进步,它需要承认,几个查询仍有待仔细考虑并解决因为预防试验计划和成为现实。
脚注
去首页Neurology.org/N为充分披露。资金信息和披露认为作者相关的,如果有的话,年底提供这篇文章。
这篇文章加工费是由马萨诸塞州总医院。
- 收到了2021年10月15日。
- 接受的最终形式2022年4月12日。
- 版权©2022年作者(年代)。发表的Wolters Kluwer健康,公司代表美国神经病学学会。首页
这是一个开放的分布式根据文章Creative Commons Attribution-NonCommercial-NoDerivatives许可证4.0 (CC BY-NC-ND),它允许下载和共享工作提供适当的引用。不能改变的工作以任何方式或使用未经许可的商业杂志。